A Randomized, Parallel Group Trial Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog) in Subjects With Type 1 Diabetes Using Basal-bolus Insulin Injection Therapy.
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2015
At a glance
- Drugs Insulin (Primary) ; Insulin glargine; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Biodel
- 07 Jun 2017 Biomarkers information updated
- 08 Sep 2013 Results published in the Media Release.
- 08 Sep 2013 Primary endpoint 'Proportion-of-glycosylated-haemoglobin - noninferiority endpoint' has been met, according to a Biodel media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History